obesity-fitness-2019-scientifictracks

8 / 13

34
Find More Information @ March 2019 Conference Series LLC Ltd
conferenceseries LLC Ltd
19th International Conference on
Obesity, Healthcare - Nutrition & Fitness
March 18 - 19, 2019 | New York, USA
Role of nonalcoholic
fatty liver disease
fibrosis score in
overweight and obese
nonalcoholic fatty liver
disease
Sandeep Garg
Maulana Azad Medical College,
India
Non-Alcoholic fatty liver
disease can occur in obese
and lean patients. Diabetes,
obesity, and hypothyroidism
are major treatable risk
factors which can prevent
the progression of NAFLD to
NASH and CLD. liver biopsy
is considered as the gold
standard for diagnosing NASH.
Fibroscan a noninvasive
technique is now being
routinely used to detect the
fibrosis of the liver. However,
this facility is not available at
every hospital. NAFLD fibrosis
score and novel biomarkers
cytokeratin 18 are being
investigated as a marker of
fibrosis. In this observational
cross-sectional study, we tried
to find out the NAFLD fibrosis
score, fibroscan values in 30
overweight (BMI> 23.5kg/
m2) and obese (BMI >28.5kg/
m2) NAFLD patients out
of total 50 NAFLD patients
diagnosed on the basis of
ultrasonography. Blood
tests including hemogram,
KFT’s, LFT’s, lipid profile and
ultrasonography and fibroscan
were done in all cases. A
value of > 0.676 was taken
as significant fibrosis,-1.455
to ≤ 0.675 as intermediate
fibrosis, <-1.455 as absence
of fibrosis. The mean age
was 46.50±12.33years. There
were 8 (26.7%) males and
22 (73.3%) females. The
mean BMI was 30.08±5.27.
The mean ALT and AST
was 54.17±27.49IU/L and
47.0±21.92IU/L respectively.
The mean total cholesterol and
triglyceride were 181.67±49.13
and 199.63±34.67
respectively. The mean TSH
was 5.87±5.09mIU/L. The
prevalence of hypothyroidism
and diabetes was 11(36.6%)
and 20(66%) respectively.
Mean NAFLD score was
-1.144±1.47 and the fibroscan
score was 7.5067±2.25. Based
on the NAFLD fibrosis score
significant, intermediate and
no fibrosis was observed
in 6.7%, 56.7%, and 36.7%
respectively.
Biography
Sandeep Garg has completed his
MBBS and MD Internal Medicine
from Delhi University. At present,
he is Professor of Medicine in
Maulana Azad Medical College
looking after the Endocrine
clinic. He is also involved in
undergraduate and postgraduate
teaching of MBBS and BDS
students, Resource person for
the HIV Fellowship, PG diploma
in Geriatrics, Hemophilia training
programme, Elsevier Clinical
Key and National Board of
Examination. He has published
more than 50 research papers,
delivered many lectures and
chaired sessions at national and
international level. Along with
many National affiliations and
awards, he is Fellow of Royal
College of Physician, Edinburgh,
and Fellow of American College
of Physician. He is also an
elected member of Physician
Research foundation of the
Association of Physicians of
India.
SCIENTIFIC TRACKS | DAY 2 JOURNAL OF OBESITY &WEIGHT LOSS THERAPY 2019, VOLUME: 4 | DOI: 10.4172/2165-7904-C2-093